Expanded Access Program to Provide Bamlanivimab (LY3819253) for the Treatment of COVID-19

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NO_LONGER_AVAILABLE

Study Classification

EXPANDED_ACCESS

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The treating physician/investigator contacts Lilly when, based on their medical opinion, a patient meets the criteria for inclusion in the expanded access program.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Expanded Access for Relatlimab

NCT05170659

NO_LONGER_AVAILABLE

Expanded Access Program of Ruxolitinib for the Emergency Treatment of Cytokine Storm From COVID-19 Infection

NCT04355793

COVID-19

NO_LONGER_AVAILABLE

A Single-Dose Study of LY3471851 in Healthy Participants

NCT04998487

Healthy

COMPLETED PHASE1

Ruxolitinib Managed Access Program (MAP) for Patients Diagnosed With Severe/Very Severe COVID-19 Illness

NCT04337359

Severe/Very Severe COVID-19 Illness

NO_LONGER_AVAILABLE

A Study of Lebrikizumab (LY3650150) Administered by Two Different Devices in Healthy Participants

NCT04840901

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

COVID-19

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Bamlanivimab

Administered intravenously (IV).

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

LY3819253 LY-CoV555

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Reside in a country where there are ongoing Lilly-sponsored clinical trials (currently this is only the United States)
* Present within 10 days of symptom onset
* Have severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) confirmed by reverse transcription polymerase chain reaction (RT-PCR) within the last three days
* Participants greater than or equal to (≥) 65 years of age OR
* Participants ≥ 12 years of age who weigh at least 40 kilograms AND have at least one of the following:

* Cancer
* Chronic kidney disease
* Chronic obstructive pulmonary disease (COPD) or other chronic lung disease
* Immunocompromised state (weakened immune system or on immunomodulatory medications)
* Obesity (body mass index \[BMI\] of 35 or higher)
* Serious heart conditions such as heart failure, coronary artery disease or cardiomyopathies
* Sickle cell disease
* Diabetes mellitus (Types 1 or 2)

* Bamlanivimab should not be used in patients hospitalized with severe COVID-19 respiratory disease

Minimum Eligible Age

12 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No